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ABSTRACT
Introduction: Clostridium difficile infection
(CDI) is the most common cause of
health-care-associated infectious diarrhea.
Recurrence rates are as high as 20–30% after
standard treatment with metronidazole or
vancomycin, and appear to be reduced for
patients treated with fidaxomicin. According
to the literature, the risk of CDI recurrence
increases after the second relapse to 30–65%.
Accurate data for Germany are not yet available.
Methods: Based on the research database of
arvato health analytics (Munich, Germany), a
secondary data analysis for the incidence,
treatment characteristics and course of CDI
was performed. The database included high
granular accounting information of about 1.46
million medically insured patients covering the
period 2006–2013, being representative for
Germany. The analysis was based on
new-onset CDI in 2012 in patients which
either received outpatient antibiotic therapy
for CDI or were hospitalized.
Results: The ICD-10 coded incidence of CDI in
2012 was 83 cases per 100,000 population.
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Overall mortality rates within the follow-up
period of 1 year were 13.5% in inpatients with
primary diagnosis of CDI, compared to 24.3% in
inpatients with secondary diagnosis of CDI
(P\0.001), and 7.1% in outpatients
(P\0.001). In the median, patients with
secondary diagnosis of CDI remained
significantly longer hospitalized (24 vs. 9 days,
P\0.001). First recurrence of CDI was observed
in 18.2% of cases with index events. There was a
significantly increased risk to suffer a second
and third recurrence, reaching 28.4%
(P\0.001), and 30.2% (P = 0.017),
respectively. Antibiotic therapy of CDI in
outpatients was performed mainly with
metronidazole (in 90.8% of index events,
60.0% of first recurrences, and 43.5% of
second recurrences).
Conclusion: The reported incidence of CDI in
Germany is higher than noted previously. The
recurrence rates do increase with the number of
relapses, but are lower than reported in the
literature, despite dominance of metronidazole
treatment in outpatients.
Funding: MSD Sharp & Dohme GmbH, Haar,
Germany.
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INTRODUCTION
Clostridium difficile infection (CDI) is the most
common cause of health-care-associated
infectious diarrhea, affecting primarily elderly
patients ([65 years) with comorbidities and
exposure to antibiotics [1–5]. At least 7–17% of
adult hospitalized patients are colonized by C.
difficile, with higher rates observed in elderly
long-term patients [4, 6]. C. difficile is also
responsible for diarrheal diseases in patients
with no risk factors (community-acquired CDI)
[1, 5, 7], and is associated with zoonotic
transmission, particularly PCR-ribotype 078
[8, 9]. Highly virulent C. difficile strains have
emerged since 2003 leading to a predominance
of PCR-ribotype 027 in many hospitals of North
America and Europe. This development is made
responsible for increased severity of illness and
increased mortality [1–5, 7, 10, 11]. In Canada, a
cumulative attributable mortality of 16.7% was
demonstrated for CDI patients after the arrival of
PCR-ribotype 027 [11]. Each case of nosocomial
CDI led, on average, to 10.7 additional days in
hospital [11]. In a Dutch case–control study, the
highest mortality was also seen among very
elderly patients and patients with PCR-ribotype
027 [12]. The occurrence of CDI was associated
with a 2.5-fold increase in 30-day mortality
compared to controls without diarrhea when
adjusted for age, sex, and underlying diseases.
CDI-related death occurred mainly within
30 days after diagnosis [12].
Recurrence rates of CDI given in the
literature are as high as 20–30% after standard
treatment with metronidazole or vancomycin
[13], and appear to be reduced for patients
treated with fidaxomicin [14–16], which
became available for treatment of CDI in
Germany at the end of 2012. According to
Surawicz and other authors, the risk of CDI
recurrence increases after the second relapse to
30–65% [17, 18]. The current overall economic
burden per CDI, addressed as direct treatment
costs, has been reported to reach between €7147
and €22,800 [19–21]. However, CDI recurrence
is particularly associated with excessive costs,
which are mostly attributable to a significantly
longer overall length of hospital stay [22]. In a
recent German study, direct treatment costs per
patient differed significantly: €18,460 in CDI
patients without recurrence, €73,900 in patients
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with recurrent CDI, and €14,530 in controls
(P\0.001) [22]. The high prevalence of CDI
itself also contributes to the economic burden.
According to the German Federal Office of
Statistics (Statistisches Bundesamt, Wiesbaden,
Germany), there is a steadily increasing number
of CDI cases (ICD-10 code A04.7) reaching more
than 30,000 primary inpatient cases and more
than 74,000 secondary inpatient cases in the
years 2013 and 2014 in Germany [23].
This paper aims to describe the current
incidence, treatment characteristics and
recurrence rates of CDI in Germany, derived
from the research database of arvato health
analytics GmbH (Munich, Germany). The
database is run by arvato in cooperation with
Gesundheitsforen Leipzig GmbH (Leipzig,
Germany), both offering independent
knowledge services and aiming to establish a
statistically valid database for health research
and analysis. Different German statutory health
insurances (voluntary development partners)
annually provide their accounting information
for this database allowing to analyze high
granular health data and insurance biographies
over several years. With coverage of patients
from all parts of the country, the population
investigated seems to be fairly representative for
the whole German population.
METHODS
Study Population and Data Analysis
Based on the research database of arvato health
analytics (Munich, Germany), a secondary data
analysis for the incidence, recurrence and course
of CDI was performed. The database used for this
purpose included high granular accounting
information of about 1.46 million medically
insured patients covering the period
2006–2013. The analysis was based on all
new-onset CDI found between 1 January 2012
and 31 December 2012 in patients who either
received outpatient antibiotic treatment for CDI
or were hospitalized. CDI-related medication
included metronidazole, vancomycin or
fidaxomicin, to verify outpatient encoding, but
data on medication were not available for
inpatients. The index dates were defined by (1)
the antibiotic prescription date as a surrogate for
outpatient CDI diagnoses, (2) the day of
admission for primary inpatient CDI diagnoses,
or (3) the date of discharge from the hospital
minus 10 days (but no less than the day of
admission) for secondary inpatient CDI
diagnoses. The latter definition tries to address
the problem of hospital-acquired CDI at an
unknown date within the hospitalization
period considering that the standard length of
antibiotic therapy for CDI is 10 days.
New-onset cases were defined as patients with
CDI documentation according to ICD-10
diagnosis A04.7 in the database, but with no
encodings for CDI or supply with a CDI-related
medication for a period of at least 60 days prior to
the diagnosis. Since inpatient diagnoses were
available for the exact date of hospital admission,
and outpatient diagnoses were documented only
quarterly due to different accounting systems,
separate patient selection algorithms had to be
applied. For inpatient diagnoses, the ICD codes
of discharge information were used. Another
criterion was the absence of CDI-related
medication (metronidazole, vancomycin, or
fidaxomicin) within 60 days prior to encoding
of ICD-10 diagnosis A04.7.
All CDI patients were followed-up for 1 year
from the index event or until death. New CDI
cases were meticulously analyzed as to whether
and how often a recurrence occurred, defined as
re-encoding of the ICD-10 code A04.7, or
outpatient diagnosis in conjunction with
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CDI-related medication, within 11–60 days of
follow-up. Events within 0–10 days of follow-up
were not counted as recurrences, because
standard CDI drug therapy extends for
10 days. Thus, encoding of a later CDI event
(C60 days) was counted as a new index event.
Events during hospitalization were further
distinguished according to primary or
secondary diagnosis of CDI. Accordingly, the
length of hospital stay (LOS) refers to the overall
LOS and not the LOS attributed to CDI.
Statistical Analysis
Statistical analysis was performed using SPSS for
Windows (SPSS 20.0; IBM, Armonk, New York,
USA). Numerical variables were summarized as
median, and categorical variables were given as
frequencies or proportions. Categorical data were
analyzed by the Chi square test or Fisher’s exact
test. For comparison of two independent groups,
the nonparametric Mann–Whitney U test was
used. P values (2-sided) of\0.05 were considered
statistically significant.
Ethics Compliance
This retrospective study was performed in
accordance with the ethical guidelines of the 1964
Declaration of Helsinki and its later amendments.
For this type of study, formal consent is not
required in accordance with the federal legislation
of the Free State of Saxony, Germany. As the study
did not modify patient management and the data
were processed anonymously, the need for
informed consent was waived.
RESULTS
In 2012, 1223 new CDI cases were identified
from a total of 1,461,268 continuously
medically insured patients. This corresponds
to 83 reported cases per 100,000 population. An
extrapolation of this sample to statutory and
private health insurances in Germany (1223 of
1,461,268 refers to 65,000 in a population of
80,000,000) results in more than 65,000 CDI
cases within Germany per year (Table 1). The
hidden incidence of CDI not treated with
CDI-specific therapy is not included in these
numbers. Thus, an underestimation has to be
assumed.
In the analyzed group of CDI cases, 1039
index events (85.0%) occurred during
hospitalization and 184 index events (15.0%)
occurred among outpatients. A total of 61.2% of
the index events (732 patients) occurred in
women, being generally more often affected by
CDI than men. Women of 80–84 years were
most frequently affected, with a total of 133
CDI patients (11.1%). In comparison, there
were only 61 male patients (5.1%) in the same
age group. The age peak in men occurred at
75–79 years (84 patients, 7.0%), slightly below
that of women. The median LOS in patients
with primary diagnosis of CDI was 9 days
(interquartile range: 6–13 days). In 55.4% of
the cases, the LOS was up to 9 days. In a further
Table 1 CDI cases identiﬁed in the research database in
2012
Patient selection CDI cases (n) Extrapolation
(n)
New CDI cases 1223 (0.083%) 65,252
Inpatients 1039 (85.0%) 55,435
Primary diagnosis
A04.7
260 (25.0%) 13,872
Secondary diagnosis
A04.7
779 (75.0%) 41,563
Outpatients 184 (15.0%) 9817
An extrapolation of this sample to other statutory and
private health insurances in Germany is given in the
righthand column
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38.1%, the LOS varied from 10 to 19 days.
Longer hospital stays were rather rare. Patients
with a secondary diagnosis of CDI remained
significantly longer in the hospital (median
24 days, P\0.001) (Fig. 1). A total of 13.5% of
inpatients with primary diagnosis of CDI (index
events) died within the follow-up period of
1 year, compared to 24.3% with secondary
diagnosis of CDI (P = 0.018). By contrast, in
the outpatient setting, only 7.1% of CDI
patients (index events) died within 1 year after
the diagnosis was encoded, revealing a
significant difference compared with
inpatients with primary diagnosis of CDI
(P\0.001). The overall mortality rates
increased significantly from index event to
second recurrence of CDI (Fig. 2).
First recurrence of CDI was observed in
18.2% of cases with index events (222 of
1223). Referring to first recurrence, there was a
significantly increased risk to suffer a second
and third recurrence, reaching 28.4% (63 of
222, P\0.001), and 30.2% (19 of 63, P = 0.017),
respectively. In 22 of 53 inpatients with primary
diagnosis of CDI (41.5%), the first recurrence
was encoded according to ICD-10 (A04.7)
within 11–19 days. In another 15.1% of cases,
recurrence of CDI was documented within
20–29 days. There was no difference regarding
the time interval to the occurrence of the first
recurrence between inpatients with primary or
secondary diagnosis of CDI. For a detailed
description of CDI recurrence rates in
inpatients and outpatients, see Fig. 3. Details
on antibiotic treatment regimens for CDI in
outpatients are given in Fig. 4. A high
percentage of patients were treated with
metronidazole for the first (60.0%) and even
for the second recurrence (43.5%). There were
no patients treated with fidaxomicin.
Fig. 1 Overall length of stay in patients (LOS, index events) with either primary or secondary diagnosis of CDI
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DISCUSSION
According to our research database, the
reported incidence of CDI in Germany in 2012
was at least 83 cases per 100,000 population.
The prevailing view in the literature clearly
shows lower incidences and gives blurred notes
on the increasing number of CDI cases in
Germany. Burkhardt et al. mention only 14.8
cases per 100,000 population in 2006 in the
Federal State of Saxony [24], but Strausberg
specifies an estimated incidence of 82 cases per
100,000 population in 2015 referring to the
reporting data of the German Institute for the
Hospital Remuneration System (Institut fu¨r das
Entgeltsystem im Krankenhaus, InEK; Siegburg,
Germany) [25]. The increased inpatient
mortality rates are strongly associated with a
high probability of increased comorbidity,
especially in patients with CDI as secondary
diagnosis.
According to various publications, 20–30%
of CDI patients suffer a recurrence after initial
treatment [13–16, 26], which is consistent with
our results and shows that this trend is at least
as high as previously assumed. According to
Surawicz and other authors, the risk of CDI
recurrence after the second relapse increases to
30–65% [17, 18, 25]. This estimate could not be
reproduced in our analysis (recurrence of CDI
was observed in 18.2% of the cases, and there
was a significant increase in the frequency of a
second and third recurrence, reaching 28.4%
and 30.2%, respectively). However, it was
generally confirmed that there is a steadily
increasing risk after each relapse for ongoing
recurrence, which is associated with a
significant increase in overall mortality
Fig. 2 One-year mortality rates of study patients depending on the recurrence of CDI
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(Fig. 2), as previously pointed out in a European
study by Bauer and colleagues [1]. According to
their findings, 40% of all deaths may be
attributed directly to CDI.
Our data include evaluation of antibiotic
treatment characteristics which reflect that
success rates of standard CDI therapies
(metronidazole and vancomycin) are limited
by (1) their non-guideline compliant use [26]
with a high proportion of metronidazole
therapy even for the second recurrence
(43.5%), and (2) their broad spectrum activity
causing considerable perturbation of the
intestinal microbiota [27]. Besides novel
therapeutic strategies with antibiotics with a
narrow spectrum of activity targeted strictly
against C. difficile showing a diminished impact
and damage on the anaerobic flora of the
Fig. 3 Recurrence rates of patients with CDI in 2012
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gastrointestinal tract such as fidaxomicin
[14, 15, 27], further innovative therapeutic
strategies for CDI are urgently needed.
Limitations
Regarding interpretation of our results, the
general limitations of a claims data-based
analysis have to be considered. Our analysis
largely depends on the quality of medical
coding, which particularly relies on given
clinical and diagnostic information, e.g.,
microbiological data and medication.
Secondary data contain only information on
services that are relevant for reimbursement.
Coding of claims may be subject to incentives
for reporting. Moreover, one has to consider
that outpatient diagnoses of recurrent CDI
without CDI-specific therapy within the same
quarter could not be detected in the dataset.
Inpatient diagnoses of recurrent CDI include
only patients being discharged between the
index date and first recurrence, or between first
and second recurrence. Therefore, a recurrence
of CDI within the same hospitalization period
could not be tracked, which could have led to a
false low recurrence rate in inpatients. To
estimate the maximum number of recurrences
within one hospital stay, the proportion of
stays longer than 25 days was stated. Although
recurrences were tracked starting from day 11
after the index date (assuming 10 days of
standard therapy), a lack of differentiation
regarding prolonged treatment of initial CDI
and treatment of a genuine relapse remains.
Regarding the assessment of mortality rates,
our analysis is weakened by missing clinical
information on the severity of CDI events.
Fig. 4 Used antibiotic treatment regimens for CDI in outpatients in 2012
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CONCLUSION
The reported incidence of CDI in Germany is
higher than noted previously (83 cases per
100,000 population in 2012 according to this
study covering the whole of Germany versus
14.8 cases per 100,000 population in 2006 in
Saxony, Germany [24]). The recurrence rates of
CDI increase with the number of relapses, but
are lower in the analyzed database than
reported in the literature [17, 18] despite the
dominance of metronidazole treatment in
outpatients. There is a strong need for novel
targeted treatment options against recurrent
CDI and preventive measures such as toxoid
vaccines.
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